Somewhat Favorable Press Coverage Somewhat Unlikely to Impact AVEO Pharmaceuticals (AVEO) Stock Price

Media stories about AVEO Pharmaceuticals (NASDAQ:AVEO) have been trending somewhat positive recently, Accern Sentiment Analysis reports. The research firm identifies negative and positive media coverage by analyzing more than twenty million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. AVEO Pharmaceuticals earned a media sentiment score of 0.08 on Accern’s scale. Accern also assigned press coverage about the biopharmaceutical company an impact score of 45.8719982092447 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the near future.

Here are some of the news stories that may have impacted Accern Sentiment’s analysis:

Several brokerages recently commented on AVEO. Zacks Investment Research lowered shares of AVEO Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Wednesday, December 6th. began coverage on shares of AVEO Pharmaceuticals in a report on Wednesday, November 15th. They issued a “buy” rating and a $5.00 price target for the company. B. Riley began coverage on shares of AVEO Pharmaceuticals in a report on Monday, November 13th. They issued a “buy” rating and a $5.00 price target for the company. Seaport Global Securities reissued a “buy” rating on shares of AVEO Pharmaceuticals in a report on Friday, October 6th. Finally, Piper Jaffray Companies lifted their target price on shares of AVEO Pharmaceuticals from $3.80 to $4.50 and gave the stock an “overweight” rating in a research note on Monday, August 28th. Two research analysts have rated the stock with a sell rating, five have issued a buy rating and one has assigned a strong buy rating to the stock. AVEO Pharmaceuticals presently has an average rating of “Buy” and a consensus price target of $4.05.

Shares of AVEO Pharmaceuticals (AVEO) opened at $3.00 on Friday. AVEO Pharmaceuticals has a one year low of $0.50 and a one year high of $4.24. The company has a current ratio of 2.33, a quick ratio of 2.33 and a debt-to-equity ratio of -0.32. The stock has a market cap of $349.05, a price-to-earnings ratio of -4.23 and a beta of 1.12.

COPYRIGHT VIOLATION WARNING: This story was reported by Community Financial News and is the sole property of of Community Financial News. If you are accessing this story on another site, it was stolen and reposted in violation of US & international copyright legislation. The original version of this story can be read at

AVEO Pharmaceuticals Company Profile

AVEO Pharmaceuticals, Inc is a biopharmaceutical company. The Company’s platform delivers insights into cancer and related disease. The Company’s product candidates include Tivozanib, Ficlatuzumab, AV-203 and AV-380. Tivozanib is a selective long half-life vascular endothelial growth factor tyrosine kinase inhibitor (VEGF TKI) that inhibits over three VEGF receptors.

Insider Buying and Selling by Quarter for AVEO Pharmaceuticals (NASDAQ:AVEO)

Receive News & Ratings for AVEO Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AVEO Pharmaceuticals and related companies with's FREE daily email newsletter.


Leave a Reply

share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit